The FDA approved Sarclisa, a CD38-targeting monoclonal antibody. The drug will face stiff competition from J&J's Darzalex, which has the same antigen target and is approved for the same population of patients.
The French drugmaker said the agency had accepted its application for isatuximab, a potential competitor to J&J's Darzalex. Positive Phase III data for isatuximab were presented at the ASCO meeting last month.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
A similar drug, Janssen's Darzalex, has already been on the market since 2014 and become well-established, with more than $1 billion in global sales last year.